New medicines that spur weight loss and address diabetes have been getting the general public—plus the pharmaceutical field—by storm. The most up-to-date entrant, Zepbound, lately joined Ozempic, Wegovy, Victoza and Other people inside of a rising class of medicine called GLP-1 receptor agonists.Even so, an off-brand Edition of the drug has bec